Presentations and Posters
- Ultimovacs NIPU Poster presentation at ESMO, September 14, 2024
- Ultimovacs INITIUM Poster presentation at ASCO, June 1, 2024
- Ultimovacs company presentation per May 7, 2024
- Business update April 17, 2024 Webcast presentation
- TENDU trial Poster presentation at AACR 2024
- Phase II NIPU trial results at ESMO presentation and discussion (31.10.2023)
- Phase II NIPU trial results at ESMO presentation (23.10.2023)
- Phase II NIPU trial result presentation (08.06.2023)
- The 103 trial presented at International Conference of the Society for Melanoma Research (18.10.2022)
- Webcast discussing the Dual Fast Track Designation (21.10.2021)
- Webcast discussing ASCO 2021 data (20.05.2021)
- Webcast discussing the DOVACC trial (11.01.2021)
- Poster presented at CIMT 2021 (Long-lasting and Dynamic Anti-hTERT Immune Responses After UV1 Vaccination)
- Poster presented at AACR 2022 (Preclinical evaluation and clinical entry of the TET platform)
- Poster presented at SITC 2021 (Translational research on Phase I study on UV1 in comb. with ipilimumab)
- Poster presented at ASCO 2021 (Data from Phase I in MM)
- Poster presented at AACR Annual Meeting 2021 (INITIUM Study Design)
- Poster presented at 2020 World Conference on Lung Cancer (NIPU Study Design)
- Poster presented at ASCO-SITC 2020 (Long Term Outcome of Phase I Study - MM)
- Poster presented at SITC 2019 (Long Term Outcome of Phase I Study - NSCLC)
- Poster presented at ESMO 2019 (Phase I MM - UV1 in combination with Pembrolizumab Study design)
- Radium Podcasts (primarily in Norwegian)
- Prospectus IPO
Publications
- Abstract: Updated survival and vaccine response from the NIPU trial (09.09.2024)
- Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial (15.08.2023)
- Therapeutic cancer vaccination against telomerase: clinical developments in melanoma (17.01.2023)
- Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination (12.09.2022)
- Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials (25.05.2022)
- Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential (05.07.2021)
- NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma (31.05.2021)
- Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma Five-Year Follow Up of a Phase I/IIa Trial (11.05.2021)
- Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer (26.11.2020)
- Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer (08.04.2017)